Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 500 shares, a decrease of 97.1% from the February 28th total of 17,500 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 365,200 shares, the days-to-cover ratio is presently 0.0 days.

Provectus Biopharmaceuticals Trading Down 8.1 %

Shares of PVCT traded down $0.01 during trading hours on Wednesday, hitting $0.09. 24,873 shares of the stock traded hands, compared to its average volume of 237,861. The business has a fifty day moving average of $0.11 and a 200-day moving average of $0.11. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.21.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.